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8ABSTRACT
Managing chronic respiratory conditions such as asthma and Chronic Obstructive 
Pulmonary Disease (COPD) forms a notable burden on the healthcare system while the 
burden on an individual is equally notable as patients might suff er from a symptomatic 
disease for decades. However, not all asthma and COPD patients develop a disabling 
disease with frequent disease exacerbations and highest cost (in Quality Adjusted Life Years 
lost or healthcare spending). Th is variation in disease trajectories enables the analytical 
identifi cation of distinct phenotypes over time. Retrospective data collected from a large 
number of patients could be used effi  ciently as the electronic health records are increasingly 
made available to researchers around the world. Th e aim of this project is to develop 
disease models based on longitudinal data to better capture the essential characteristics of 
obstructive lung disease, mainly focusing on COPD.
Projects I – III in this thesis are based on 2398 asthma and COPD patients retrospectively 
followed through electronic health records from year 2000 onwards. We aimed to analyse 
this real-world hospital based data using Hierarchical Models to assess the variation of 
development between individual patients over time. Unpublished Project IV is based on 
Health 2000 to 2011 follow-up study consisting of 1113 subjects from random Finnish 
population. Th e aim was to estimate Single Nucleotide Polymorphism (SNP) based 
heritability of Forced Expiratory Volume in 1 s (FEV1) level and development and to perform 
a Genome-Wide Association Study (GWAS) to identify possible genetic markers associated 
with FEV1 development over time.
Our results suggest that the major determinants of Health Related Quality of Life (HRQoL) 
in mild or moderate COPD are the common comorbidities associated with COPD while 
in severe diseases the accentuated lung function has a major role. Over time, observable 
individual trajectories of HRQoL are presented in Asthma and COPD. Signifi cant decline 
of HRQoL in Asthma was found to associate with obesity related diseases and states while 
the main determinants in COPD were poor lung function and increasing age. Psychiatric 
conditions were found associated in both Asthma and COPD.
Using an unbalanced data (varying number of measurements and length of follow-up time) 
of lung function measurements, we were able to observe signifi cant individual trajectories of 
FEV1 based on the past development. Signifi cant and rapid decline was seen in 30% of the 
COPD cohort in the study while signifi cant improvement was extremely rare. Rapid decline 
was associated with numerous exacerbation related markers.
Our unpublished results suggest that development of FEV1 is signifi cantly aff ected by 
common variants in DNA as genetic eff ects were estimated to explain 1/3 of the phenotypic 
variance in random Finnish population. One locus previously associated with the level of 
9FEV1 was found associated with the development of FEV1. Suggestive evidence for two novel 
loci associated with FEV1 development was also identifi ed.
Th e fi ndings underline the varying trajectories of HRQoL and lung function seen in a 
homogenous cohort of Asthma and COPD patients.
Th is thesis aims to provide approaches and aspects to better understand the trajectories of a 
chosen parameter in asthma and COPD. Th e variation of e.g. lung function development is 
abundant, and we should not consider this variation as an obstacle but as a useful source of 




Krooniset ahtauttavat keuhkosairaudet, kuten keuhkoahtaumatauti (COPD) ja astma ovat 
merkittäviä kansansairauksia Suomessa. Jopa lähes kymmenys maan aikuisväestöstä kärsii 
astmasta, COPD:n esiintyvyys ikääntyneillä miehillä saattaa olla vielä tätäkin suurempi. 
Kroonisina tiloina ahtauttavat keuhkosairaudet aiheuttavat huomattavan taakan niitä 
sairastaville potilaille sekä suuria kustannuksia yhteiskunnalle.
Merkittävä riskitekijä vaikealle keuhkosairaudelle on tupakointi, joka on tunnettu 
riskitekijä myös monelle muulle krooniselle sairaudelle. Kuitenkin vain osa tupakoivista 
ahtauttavaa keuhkosairautta sairastavista omaa voimakkaasti etenevän sairauden, joka 
pahimmillaan johtaa toistuviin intensiivistä hoitoa vaativiin sairauden pahenemisvaiheisiin 
ja ennenaikaiseen kuolemaan. Nykyisellään suuri osa resursseista kulutetaan intensiivisessä 
hoidossa, eikä niiden ennaltaehkäisyssä. On mahdollista, että etenevän ja huomattavia 
kustannuksia aiheuttavan keuhkosairauden taustalla on sille ominaisia perinnöllisiä tai 
ympäristöllisiä riskitekijöitä. Nämä riskitekijät ovat kuitenkin nykyisellään huonosti 
tunnettuja.
Keuhkosairaus aiheuttaa oireita vasta keuhkojen toiminnan heikennyttyä jo merkittävästi, 
jonka jälkeen potilaan toimintakyky heikkenee nopeasti, mikäli sairaus edelleen etenee. 
Mikäli huonosti kehittyvät potilaat kyettäisiin paremmin tunnistamaan aikaisessa vaiheessa, 
olisi mahdollista kohdistaa hoito ja interventiot niitä eniten tarvitsevaan ryhmään. 
Tässä työssä on tutkittu erityisesti COPD:tä ja astmaa sairastavien potilaiden terveyteen 
liittyvän elämänlaadun ja keuhkojen toiminnan kehitystä yli ajan. Noin 30 %:lla COPD-
potilaista nähtiin tilastollisesti merkitsevää laskua keuhkojen toiminnassa. Heikosti 
kehittyvät potilaat kärsivät myös muita useammin sairauden pahenemisvaiheista. Huonolle 
elämänlaadulle COPD:ssä ja elämän laadun kehitykselle astmassa ja COPD:ssä tunnistettiin 
useita kliinisiä riskitekijöitä. Työssä tarkasteltiin lisäksi väestöaineistossa nähtyä keuhkojen 
toiminnan muutosta, jolloin noin kolmanneksen vaihtelusta nähtiin selittyvän geneettisillä 
tekijöillä.
Väitöstyön aineisto on kerätty takautuvasti, mutta kattavasti erilaisista sairaala- ja 
rekisterilähteistä sekä toistuvin kyselytutkimuksin. Sairaala-aineisto edustaa aitoa 
potilasmateriaalia, jota ei ole tutkimusta käynnistettäessä merkittävästi rajattu. 
Ainutlaatuisen materiaalin analysoimiseksi on käytetty kehittyneitä tilastollisia menetelmiä, 
jotka mahdollistavat yksittäisten potilaiden kehityskulun arvioimisen yli ajan. Nämä 
menetelmät ovat helposti käyttöönotettavissa myös sairaaloiden tietokannoissa, jolloin 




1  INTRODUCTION 
Asthma and Chronic Obstructive Pulmonary Disease (COPD) belong to the category of 
obstructive lung diseases due to the airfl ow limitation, which is manifested during expiration. 
Th is obstruction of expiratory airfl ow can be divided based on anatomical structures as in 
asthma the obstruction is seen in the larger airways (Maddox, Schwartz 2002) and in COPD 
the most aff ected airways are the smallest ones (Hogg 2004). Asthmatic symptoms are oft en 
varying in time and are caused by airway infl ammation and bronchial hyper-responsiveness 
leading to variably occurring airfl ow limitation (Global Initiative for Asthma (GINA) 
2015). Th is expiratory airfl ow limitation is considered reversible aft er bronchodilation in 
spirometric testing (Pellegrino et al. 2005). Asthma oft en fi rst expresses in childhood or in 
early adulthood and as age increases, the prevalence of COPD becomes more pronounced. 
COPD is rarely seen in 40-year-old or younger people without alpha-1-antitrypsin 
defi ciency. Th e most important risk factor for COPD is tobacco smoke whereas especially in 
low-income countries the exposure to toxic fumes from burning biomass fuels plays a major 
role (Salvi, Barnes 2009). COPD is characterized by non-reversible airway obstruction in 
expirium due to resistance in the smallest airways. Elevated resistance in smallest airways 
is due to chronic bronchitis and collapsing of lung structure aft er infl ammatory response 
(Hogg 2004). In contrast to asthma, the airfl ow limitation in COPD is non-reversible and 
oft en progressive if exposure to noxious stimuli continues (Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) 2015). Adult populations oft en constitute diagnostic 
challenges as incomplete responses to administered bronchodilators in asthma (Kauppi, 
Kupiainen et al. 2011, Lee et al. 2007) and clinically signifi cant bronchodilation in COPD 
(Albert et al. 2012) are seen. Patients with characteristics from both asthma and COPD 
could be seen having Asthma-COPD Overlap Syndrome (ACOS) (Bateman et al. 2015). 
Asthma is also a known major risk factor of COPD (Silva, Sherrill et al. 2004).
As the diagnosis of most diseases, including obstructive lung diseases, is oft en made cross-
sectionally at a certain period of time, the development of relevant parameters is not assessed 
at the time of diagnosis. Th is is well-suited to match the needs of practicing medicine when 
a patient is very rarely followed to gain a diagnosis, but ill-suited to match the needs of 
accurate diagnosis. Th e fundamentals of diagnostics are stagnant in time while it might be 
extremely useful to follow e.g. response to treatment, quality of life or lung function over 
time to determine the relevant characteristics of each patient.
Under each obstructive lung disease, many distinct phenotypes exist both in asthma 
(Wenzel et al. 2012) and in COPD (Turner et al. 2015), each presenting with characteristic 
underlying disease processes leading to a certain clinical status. Some of the already known 
or yet unknown phenotypes could be identifi ed based on longitudinal development of a 
certain parameter, say, lung function over time. As the concept of identifying change on 
an individual patient-level is not widely known in the fi eld of clinical medicine, the aim 
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of this study is to provide better understanding and tools for interpreting longitudinal 
change. As this study shows, there is an abundant variation in the trajectories of each patient 
even though diagnosis and other relevant criteria are matched. Th is variation should not 
be regarded as a nuisance but as valuable information of each patient’s own characteristic. 
Th e uncertainty related to a specifi c trajectory might also be considered an advantage in 
the analysis, in cases where some trajectories could be considered signifi cant in contrast to 
uncertain ones. Signifi cant trajectories could be statistically weighted more to avoid biased 




2    LITERATURE REVIEW
2.1  Asthma, COPD and Asthma COPD Overlap Syndrome (ACOS)
Th e key component in obstructive lung disease is the impaired expiratory airfl ow. Th e 
natural history of these three diseases diff ers markedly for asthma and COPD but the 
processes are localized mainly on the conductive airways. Conductive airways deliver the air 
to the bronchi from pharynx/larynx and do not take part in the gas exchange process, which 
takes place in the respiratory bronchioles.
Asthmatic airfl ow limitation is most oft en initiated by eosinophilic chronic infl ammation 
in the airways leading to hyper-responsiveness in the surrounding smooth muscles fi nally 
causing the variable airfl ow limitation (Anderson et al. 2008). Th ickening of basement 
membrane further obstructs the airways. Airfl ow limitation in asthma is considered 
reversible spontaneously or aft er administration of bronchodilators. Th e infl ammation can 
be repressed with the use of corticosteroids, usually as administered as an inhalation.  Th e 
overall response to therapy and prognosis in asthma is good, however, some forms of asthma 
are related to poor prognosis and frequent disease exacerbations. Numerous phenotypes 
(subgroups with distinct observable characteristics) in asthma have been suggested, e.g. 
allergic, eosinophilic and non-eosinophilic, neutrophilic, exercise induced, obesity related, 
aspirin sensitive and occupational asthma (Turner et al. 2015, Wenzel et al. 2012).
In COPD, noxious stimuli such as tobacco smoke, is the most common cause of 
infl ammatory process, which takes place in the lungs and localizes in the smaller airways 
(diameter <2mm) compared to asthmatic patients. Th e infl ammatory process (Barnes 
2014) stimulates mucous hypersecretion exacerbated by the loss of ciliary function leading 
to diffi  culties in expiratory airfl ow. If persistent, the condition is considered to be chronic 
bronchitis that very oft en precedes clinical COPD. Airway remodelling might occur leading 
to narrowed diameter of bronchioles obstructing the airfl ow. If noxious stimuli continue or 
the person is prone to the infl ammatory process in question, the balance of proteolysis and 
antiproteolysis in lungs is disturbed leading to destruction of alveolar structure, normally 
responsible for gas exchange. Proteolysis leads to loss of elastic recoil in alveolar walls and 
surrounding structures resulting in air-trapping during expiration. Dilation of alveolar 
walls leads to fusion of alveolus, also known as emphysema. Emphysema leads to decreased 
diff usion capacity of the alveolus due to decreased area for gas exchange when small alveoli 
form larger spaces (Hogg 2004. However, not all these processes are necessarily found in a 
particular COPD patient. Th e fi rst phenotypes in advanced COPD were the Blue Bloater 
and Pink Puff er (Dornhorst 1955) as Pink Puff er represented an older patient with advanced 
emphysema and severe dyspnea. Blue Bloater in contrast represented a younger patient 
with chronic bronchitis, recurrent disease exacerbations and commonly suff ering from 
congestive heart failure. Th ese phenotypes are crude generalizations and only off er insight 
to COPD as an umbrella diagnosis and numerous phenotypes have since been suggested 
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(Turner et al. 2015). In COPD the mainstay of therapies are muscarinic antagonists and beta-
2-adrenergic agonists aimed to decrease air-trapping and mucous hypersecretion. Disease 
exacerbations oft en associate with infections, viral or bacterial and occasionally require 
cures of corticosteroids or antibiotics. Th e key component to curbing the development of 
obstruction is avoiding the noxious stimuli causing COPD.
Th e prevalence of ACOS depends largely on the diagnostic criteria used. Patients with severe 
or diffi  cult-to-treat asthma have been found with persistent airfl ow limitation of up to 60% 
(Lee et al. 2007) while coexistent asthma and COPD diagnosis have been found in less than 
20% (Kauppi, Kupiainen et al. 2011, Andersen et al. 2013, Pleasants et al. 2014). Clinically, 
patients with ACOS are oft en found with poor lung function compared to COPD patients 
even though they present less extensive smoking history while comorbidities and disease 
exacerbations contribute to the condition as well (Nielsen et al. 2015).
2.2  Health Related Quality of Life in Asthma and COPD
Self-administered questionnaires are frequently used to assess the Health Related Quality 
of Life (HRQoL) and disabilities caused by obstructive lung disease. Th e purpose of the 
questionnaires is oft en to provide a summary score (or multiple scores) allowing comparison 
between patients, patient‘s development over time or to evaluate treatment outcomes. Th e 
questionnaires can be divided based on their focus, whether it is on general health or on 
disease specifi c HRQoL. Generic questionnaires are used for gaining information about 
the patient’s general state of health, such as 15D (Saarni, Harkanen et al. 2006), the most 
commonly used questionnaire in Finland. Th is is done to estimate the overall burden 
of separate and overlapping diseases or states aff ecting the patient‘s HRQoL. Generic 
questionnaires also allow the comparison of the general population to age or gender matched 
patients to quantify e.g. Quality Adjusted Life-Years lost due to a disease. When using a 
generic questionnaire in a study of a specifi c disease, it should be noted that other diseases 
could have a confounding eff ect on the HRQoL if a patient is mainly suff ering from the other 
disease and not the one of interest. However, this eff ect might be observed with a disease 
specifi c questionnaire when the eff ects of comorbidities provoke pulmonary symptoms 
as in e.g. congestive heart failure. Th e ability to observe HRQoL in a wide perspective is a 
major advantage of the generic questionnaires as diseases might have an impact through yet 
unknown mechanisms manifesting themselves in diff erent organ systems. 
Th e focus of the disease specifi c questionnaires such as Airway Questionnaire 20 (AQ20) 
(Hajiro, Nishimura et al. 1999) is on a specifi c disease or an organ system and its symptoms 
or limitations possibly aff ecting HRQoL. Th ey are frequently used for the obstructive lung 
disease as the responsiveness is found superior to generic questionnaires (Puhan, Guyatt et 
al. 2007). HRQoL has been found lowest in patients with ACOS while patients with asthma 
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have better QoL compared to COPD patients as comorbidities and gender also contribute to 
HRQoL (Kauppi, Kupiainen et al. 2011, Laitinen, Hodgson et al. 2009).
2.3  Co-morbidi? es and lung func? on on HRQoL in Asthma and 
COPD
Although the hallmark of COPD is progressive airfl ow limitation, many other diseases or 
states contribute to the HRQoL as well. Airfl ow limitation has not been found suffi  cient in 
predicting the outcome of COPD and correlations between lung function parameters and 
HRQoL have been modest at most. Asthma is commonly associated with chronic rhino-
sinusitis, allergic rhinitis and other atopic diseases, obesity and sleep apnoea (Baiardini, 
Braido et al. 2006, Braido, Bousquet et al. 2010, Beuther, Sutherland 2007) while COPD 
has been associated with cardiovascular diseases, diabetes, osteoporosis, kidney and 
heart failure, musculoskeletal dysfunction, anxiety, depression, addiction diseases and 
cancer (Corsonello, Antonelli Incalzi et al. 2011, Wijnhoven, Kriegsman et al. 2001, Leidy, 
Coughlin 1998, van der Molen, Postma et al. 1997, Marks, Dunn et al. 1993, Curtis, Deyo 
et al. 1994, van Manen, Bindels et al. 2001, Burgel, Escamilla et al. 2013). Th e background 
of multimorbidity in COPD remains to be determined, but systemic infl ammation has been 
hypothised as the primus motor, provoked by tobacco or other biomass smoke (Barnes 
2010). Th e shared comorbidities possess common risk factors such as tobacco smoking, but 
the web of causality is poorly understood. Th e determinants of the poor development of 
HRQoL are not well known, but increasing age, smoking, non-compliance to medication, 
dyspnoea and low Peak Expiratory Flow (PEF) have been found to be associated with the 
decline in asthma while male gender, low bodyweight, physical inactivity and respiratory 
symptoms have been found associated in COPD (Hesselink, van der Windt et al. 2006).
2.4  Natural history of a disease requires longitudinal assessment 
Th e natural history of a disease is used to describe how a clinical state is achieved in a process 
with three phases (Natural History of Disease 2008):
• Pathological onset
• Pre-symptomatic change, from the pathological onset to the fi rst symptoms
• Clinical disease
A number of prospective studies have been performed to capture the essential determinants 
of each disease’s natural history, e.g. Framingham Heart Study (Dawber, Meadors et al. 
1951) initiated in 1948 to better understand the role of blood pressure as a risk factor of 
cardiovascular diseases. In the case of COPD, the concept of diff erent susceptibility to 
tobacco smoke was established by the seminal study (Fletcher, Peto 1977), supportive data 
was later presented (Burrows, Knudson et al. 1977, Burrows 1990). Even though these studies 
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confi rmed the role of tobacco smoke and diff erential susceptibility to it, the natural history 
of COPD remains to be under investigation as it is evident that important determinants of 
disease progression are still to be found (Mannino, Watt et al. 2006). 
Th e examination of the natural history of a disease requires longitudinal studies to assess the 
risk factors of diff erent paths e.g. to poor lung function as the follow-up time of 8 years in 
the seminal study by Fletcher and Peto is arguably short to fully describe the characteristics 
of COPD (Rennard, Vestbo 2008). Further studies are needed to assess the following 
basic epidemiological eff ects of time in COPD: the age, period eff ects and their possible 
interactions (Szklo, Nieto 2014a).
2.5  Lung func? on and its development in COPD
While fi xed airfl ow limitation is characteristic of COPD (Mannino, Watt et al. 2006), there 
are, however, numerous phenotypes in COPD (Han, Agusti et al. 2010, Friedlander, Lynch 
et al. 2007) such as the frequent exacerbator, emphysema dominant, airway dominant and 
(lung function) rapid decliners. 
Rapid decline of Forced Expiratory Volume in 1 s (FEV1) usually considered as >50ml/
year, has been shown to be associated with morbidity and mortality (Beeckman, Wang et al. 
2001, Baughman, Marott et al. 2011, Ryan, Knuiman et al. 1999). Rapid decline might also 
be associated with other phenotypes such as the frequent exacerbator and airway hyper-
responsiveness (Han, Agusti et al. 2010, Anzueto 2010). Development of lung function has 
been shown to be highly variable in COPD (Nishimura, Makita et al. 2012, Vestbo, Edwards 
et al. 2011, Casanova, de Torres et al. 2011, Tantucci, Modina 2012, Qureshi, Sharafk haneh 
et al. 2014). As the variation in FEV1 development is abundant, there is a need to identify the 
rapid decliners at an individual level (Tashkin 2013) in contrast to mean values of group level 
decline. Th e group level decline is used to account for random error of individual trajectories 
as the grouping is oft en based on the distribution of individual trajectories, thus discarding 
the uncertainties related to the individual study subjects. Reliable trajectory estimates require 
a clinically valid follow-up time with the minimum of 3 measurements of lung function. 
Assessing the individual trajectories makes use of the uncertainties as an unknown fraction 
of apparent trajectories with 2 measurements are due to random errors. Trajectories based 
on 2 measurements do not include the information about the individual level variation and 
using 2 measurements requires a longer follow-up time and higher validity and reliability to 
allow solid inferences of the development. Th us trajectories in this thesis are seen as patient 
specifi c trends over time, consisting of minimum 2 measurements over clinically valid time.
As the phenotypic variance seen in e.g. lung function can be divided to environmental and 
to genetic sources, the development of lung function should be thoroughly assessed and 
understood to allow for further analysis of its determinants.
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2.6  Heritability of lung func? on and its development
Heritability estimates can be produced in familial or twin studies or by taking advantage of 
the genotyped and shared variants of a DNA sequence. Single Nucleotide Polymorphism 
(SNP) based heritability of lung function level has been assessed in a study enriched with 
heavy smokers suggesting that 38% of FEV1 variation in non-Hispanic whites and 51% in 
African Americans is due to genetic eff ects (Zhou, Cho et al. 2013). Pedigree estimates of 
lung function level have produced similar but variable estimates depending on the source 
population and the spirometric parameter (Wilk, Djousse et al. 2000, Ingebrigtsen, Th omsen 
et al. 2011, Klimentidis, Vazquez et al. 2013). Development of lung function assessed in a 
cohort of elderly never smoking female twins found that while a third of variation of cross-
sectional lung function is due to genetic eff ects, their contribution in the development of 
FEV1/FVC is substantially lower (Hukkinen, Kaprio et al. 2011). Even lower estimates were 
produced in a familial study of elderly population with estimates from 5% (FEV1) to 18% 
(FVC) but when restricted to concordant for smoking status the estimates were somewhat 
higher, 18% to 39% respectively (Gottlieb, Wilk et al. 2001). SNP-based and familial 
estimates have been shown to produce parallel estimates (Klimentidis, Vazquez et al. 2013). 
Heritability of lung function development has thus been assessed only in familial or twin 
studies and never using SNP-based analysis. 
Also, when the heritability of multiple phenotypes (FEV1/FVC, emphysema, gas trapping) 
related to COPD was estimated, it was found that the heritability of COPD disease status 
was 38% (Zhou, Cho et al. 2013).
2.7  Gene? c suscep? bility to poor lung func? on and COPD
During recent years, a number of loci have been found to associate with the level of lung 
function (22 associated with FEV1/FVC and 7 with FEV1, Table 1.) (Hancock, Eijgelsheim 
et al. 2010, Repapi, Sayers et al. 2010, Soler Artigas, Loth et al. 2011) while they only explain 
some 3% of the variation seen in FEV1/FVC and 1.5% of the variation in FEV1 (Soler Artigas, 
Loth et al. 2011). 
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Table 1. Previously identifi ed loci associated with FEV1 level and development.
Locus Chromosome Trait
MECOM 3 FEV1 level
ZKSCAN3 6 FEV1 level
CDC123 10 FEV1 level
C10orf11 10 FEV1 level
HTR4 5 FEV1 level
TNS1 2 FEV1 level
GSTCD 4 FEV1 level
ME3 11 FEV1 development
IL16/STARD5/TMC3 15 FEV1 development
DLEU7 13 FEV1 development
Th e susceptibility for poor development of lung function has been assessed twice (Imboden, 
Bouzigon et al. 2012, Tang, Kowgier et al. 2014), the fi rst one stratifi ed for asthma status. 
In the stratifi ed analysis a DLEU7 locus associated with FEV1-development was replicated 
while the large meta-analysis revealed one locus on ME3 at genome-wide signifi cance in a 
sub-cohort with >2 measurements and another suggestive locus in IL16/STARD5/TMC3. 
Th e known loci, however, explain only a small fraction of variation seen in lung function 
development considering the heritability estimates for lung function development.
For COPD, seven loci have been identifi ed (Pillai, Ge et al. 2009, Cho, Boutaoui et al. 2010, 
Cho, McDonald et al. 2014) while again the known loci (Table 2.) explain only a minority of 
this variation due to genetic eff ects (Cho, Castaldi et al. 2012).
A known predisposition to emphysematic disease is the alpha-1-antitrypsin defi ciency 
(Laurell, Eriksson 1963) due to mutated SERPINA1 gene is present in 1–3% of COPD cases 
(Cohen 1980).
Table 2. Loci associated with COPD disease status.
Locus Chromosome Trait
CHRNA3/5/IREB 15 COPD disease status
FAM13A 4 COPD disease status
HHIP 4 COPD disease status
RIN3 14 COPD disease status
MMP12 11 COPD disease status
TGFB2 1 COPD disease status
CYP2A6/EGLN2/RAB4B 19 COPD disease status
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2.8  Ques? onnaires and tests in studying obstruc? ve lung disease
Th e validity of a questionnaire or a test is a feature with which the ability to approximate a 
true but unknown parameter (e.g. HRQoL or FEV1 level) is estimated. Reliability is another 
feature of a test, and it measures how the estimated parameter would change if the test was 
repeated. Validity and reliability thus have a relationship aff ecting the interpretation of the 
estimates.
Th e validity of a questionnaire is commonly assessed by comparing the questionnaire in 
question to the golden standard by means of correlation or other statistical measure. In 
the fi eld of HRQoL of asthma and COPD, the St. Georges Respiratory Questionnaire 
(Jones 1992) is considered the golden standard in pulmonary diseases to which both 
of the questionnaires used in this study have been compared (Kauppinen, Sintonen et al. 
1998, Mazur, Kupiainen et al. 2011, Hajiro, Nishimura et al. 1999) while reliability has also 
been assessed (Stavem 1999, Barley, Quirk et al. 1998). Th e reliability and repeatability are 
important measures when measured cross-sectionally, and they become even more vital 
when used in longitudinal studies as the uncertainty related to an individual trajectory is 
assessed as more sources of variation are introduced when measured repeatedly.
 
2.9  Bias in epidemiological study
Erroneous interpretation of the results might be due to many sources causing a systematic 
bias in the results, but they can be roughly divided into selection and measurement biases 
and confounding. 
In the case of selection bias, study participants are selected with a diff erent probability from 
the target population based on some characteristic. Th is characteristic might be of interest 
regarding the study in question and thus distort the inferences. Problems arise if the study 
aims to depict the whole population, but only a sub-population is included due to e.g. 
recruitment or follow-up process. Th e selection probabilities are then aff ected by exposure 
or disease status (Dos Santos Silva 1999). 
Th e measurement bias can yet be subdivided into misclassifi cation bias, ecological fallacy 
and regression towards the mean. Th e misclassifi cation bias is due to measurement error 
of exposure or outcome status due to the lack of validity or reliability of questionnaire or 
test. Sources of misclassifi cation bias are recall, interviewer, reporting and detection biases. 
Recall bias is a form of misclassifi cation bias relevant in questionnaire-based data when a 
patient’s past answers have a diff erential impact on the present questionnaire depending 
on the case-control status. Interviewer bias might appear during interviews, but also lung 
function testing could be aff ected by the spirometry staff . Reporting bias might happen 
unknowingly or knowingly when reporting is aff ected by the intercourse with the researcher. 
Literature Review
20
Detection bias occurs when a risk factor in question directs to diagnostic procedure, which 
then leads to excess diagnosis in the exposed. Ecological fallacy takes place when the fi ndings 
made at group-level are generalized to the individual level. Here ecology refers to a diff erent 
geographical localization of groups based on which the inferences are made, but broadly 
the fallacy could take place even within the same region. As in smokers, the decline of lung 
function is known to be steeper on average, but this is not necessarily true for all individuals 
as some may not suff er from tobacco smoke. Regression towards the mean is a phenomenon 
related to extreme values collected at the start of a follow-up period. Th ese extreme values 
have a tendency to shift  towards the mean value of the distribution over time as they have a 
higher probability to be erroneous (Delgado-Rodriguez, Llorca 2004).
Confounding variables diff er from other sources of bias in the sense that they truly exist, 
in contrast to other sources of bias that are due to erroneous study design. Th erefore, 
confounding variables need to be taken into account when plausible and useful models are 
developed. Confounding variables are:
• considered to be causally linked to the outcome of interest (a direct risk factor or a 
proxy),
• considered to be causally or non-causally linked to the exposure in question,
• not considered to be in between of exposure and outcome in the web of causality.
Random error is not a source of bias as it is random by defi nition and does not aff ect the 
estimate but only the uncertainty related to the estimate. Random error can be compensated 
by increasing the number of samples (Delgado-Rodriguez, Llorca 2004, Szklo, Nieto 2014b).
2.10  Retrospec? ve data and Electronic Health Records 
In retrospective studies, the outcome and exposures are determined at the initiation phase 
of the study, and associations of exposures are estimated in a retrospective manner, while 
in prospective studies the exposure is measured during the follow-up while waiting for the 
outcome. In prospective studies it is thus possible to plan for data collection systematically 
to avoid exposure misclassifi cation while this is not possible in retrospective studies. Major 
challenges epidemiologically and analytically are incomplete data and accuracy of the data 
due to selection and misclassifi cation bias, which can both cause major misinterpretation 
of the results. As prospective studies possess qualities superior to retrospective studies, they 
suff er from higher cost and a time lag from study initiation to the analysis of the results.
Health record data is oft en recorded only in the case of an event (Hripcsak, Albers 2013) 
which is usually unfavourable to health and thus the data collection is not systematic as 
in prospective studies. Missing data could be due to no event or due to event not recorded 
when it should have been recorded. Data collection is enriched in patients receiving more 
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intensive care and examination while the non-exposed are exempt from attention from the 
medical system. Data is oft en missing not at random, but the missing data is diff erentially 
distributed in the exposed and non-exposed, and the use of analytical methods to account 
for confounding (e.g. multivariate regression) might further aggravate the selection bias. 
Th us health record data always includes sources of bias and cannot be used as data collected 
at clinical trials as is, but needs further assessment (Weiskopf, Weng 2013). 
2.11  Healthcare data in research use
Electronic health records (EHRs) data is abundantly collected for medical decision-making 
in clinical setting and is used by medical professionals such as medical doctors to enable 
the diagnosing and treatment of diseases and conditions. Aft er clinical decision-making this 
data has little use other than its potential for research activities.  
EHRs data could, however, be used to defi ne phenotypes in high-throughput manner to 
refi ne the clinical data for use in machine learning (Hripcsak, Albers 2013). Possibly the 
greatest potential of EHRs is in the ability to combine it with other registry and genetic data 
collected during normal clinical practice (Kohane 2011). Genotype data could be used in 
conjunction with the whole phenome data at once in contrast to one phenotype-genotype 
association (Choi, Kim et al. 2013). Th e use of electronic healthcare data is, however, limited 
by numerous legal and ethical issues (Taylor 2008).  
Systematic bias using EHRs data could, however, persist even aft er phenotyping and needs 
to be taken into account whenever using machine learning methods to analyse the EHRs 
data (Jensen, Jensen et al. 2012). 
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3  AIMS OF THE STUDY
Th e aim of this thesis was to develop analytical approaches to make use of electronic 
health care records (EHRs) in identifying trajectories manifesting over time in asthma and 
COPD. Trajectories are not widely used in the fi eld of clinical medicine, where longitudinal 
inferences are generally made comparing mean values at the start and at the end of a 
follow-up time. Th e use of EHRs necessitated the use of fl exible methods for the following 
reasons: the data includes missing values, measurements are not evenly spaced in time and 
follow-up times vary depending on patient. Th e parameters under investigation were Health 
Related Quality of Life and lung function. Th e specifi c aims were:
• to assess the eff ect of common comorbidities on the HRQoL in asthma and COPD,
• to study whether the development of the chosen parameters would present inter-
individual variation in asthma and COPD patients,
• to study whether individual trajectories of HRQoL and FEV1 could be identifi ed and to 
assess their association to clinical determinants,
• to quantify the variation of FEV1 development due to genetic markers in prospective 
data and to possibly identify genetic markers associated with the development.
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4  MATERIAL AND METHODS 
4.1  Finnish Chronic Airway Disease (FinnCAD) cohort
Th e cohort used in the Projects I–III is collected from Helsinki and Turku University 
Central Hospitals and discharged with ICD10 J44 and J45 codes during years 1995–2006. 
Th e Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District 
(Coordinating Ethics Committee decision 125/E0/04) has approved the study, and the 
permission to conduct research was granted by the Helsinki and Turku University Hospitals. 
Th is cohort consists of 2395 asthmatics, smoking related chronic bronchitis or COPD and 
Asthma-COPD Overlap Syndrome (ACOS) patients, whose medical records were collected 
retrospectively from 5–10 years prior to study enrolment during years 2005–2007. Th orough 
examination of the clinical and diagnostic data was done to determine the main components 
of the obstructive lung disease as asthma (1329 patients), COPD (739 patients) and ACOS 
(347 patients), following the GOLD (Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) 2015) and GINA (Global Initiative for Asthma (GINA) 2015) guidelines. All 
COPD and ACOS patients had a smoking related disease and reversibility in spirometry was 
required for ACOS diagnosis. Common comorbidities were determined at the time of recruit 
based on diagnosis, oft en made by a specialist. Patients will be followed every other year 
until 10 years has passed from study enrolment while HRQoL, working ability, medicine use 
and smoking habits are being collected prospectively. During recruitment, blood samples 
were taken for later analysis. Descriptive data of patients in the cohort are given in the Table 
3. 
Table 3. Descriptive characteristics of FinnCAD-cohort used in Projects I–III. The data is presented 
as % of the total or mean (SD) unless stated otherwise. Smoking status is collected in conjunction 
from medical records and follow-up data.
Total N=2398 Asthma, N=1329 COPD, N=739 ACOS, N=347
Male % 26% 64% 47%
Year of Birth, range 1951 (12.5), 54 1942 (6.8), 46 1944 (6.9), 35
FEV1 % 86.5% (18%) 57.2% (19%) 58.4% (19%)
FEV1/FVC% 78.8% (9%) 63.8% (14%) 63.6% (14%)
Pack Years 8 (13) 42 (17) 16 (39)
Current smokers 123 235 126
Ex-smokers 528 484 221
Non-smokers 678 0 0
Age at onset of obstructive 
lung disease 43 (16) 58 (7) 53 (11)
Hypertension 34% 41% 41%
Diabetes 7% 15% 14%
Alcohol abuse 4% 15% 20%
Psychiatric condition 30% 33% 40%
Body Mass Index 27.4 (5.5) 27.0 (5.5) 27.6 (6.5)
15D score at inclusion 0.86 (0.1) 0.79 (0.1) 0.79 (0.1)
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4.2  GenMets cohort
Cohort used in the Project IV consists of random sample of Finnish adult population for 
Health 2000 Survey Cohort (Heistaro 2008) with a follow-up on year 2011. Th e GenMets 
subcohort consists of 919 metabolic syndrome cases and 1219 matched controls genotyped 
with Illumina 610K chip. Valid pre-bronchodilatory spirometry at both baseline and 
follow-up was available for 1113 subjects (Table 4.). Asthma and COPD were determined 
based on interviews.
Table 4. Descriptive characteristics of the cohort used in Project IV. Th e data is presented as N, % of 









Obstructive lung disease (Asthma/COPD) 7%
Body Mass Index 27.1 (4.3)
4.3  Sta? s? cal analysis
4.3.1  Comorbidi? es in COPD – A cross-sec? onal analysis
In Project I linear and logistic regression was used to assess the determinants of HRQoL 
as continuous and binary (very low HRQoL vs. others) as an outcome. Final models were 
built using backwards stepwise regression based on Akaike Information Criterion (AIC). 
Regression estimates from linear regression for HRQoL were standardized to compare the 
eff ects of each independent variable on the HRQoL as the scales on independent variables 
vary. Unadjusted and adjusted coeffi  cients from regression models were given to allow 
solid assessment of the results as possible confounders are included in adjusted models. 
Spearman’s correlation coeffi  cient was used to allow assessment of nonlinear correlations 
and non-normal distributions of variables. Diff erences in the mean values of the estimated 
parameters between patient groups were determined using ANOVA (Analysis of Variance) 
followed by Tukey’s Honestly Signifi cant Diff erence as a post-hoc test. Receiver Operator 
Characteristic (ROC) and Area Under the Curve (AUC) statistic were determined to assess 
the ability of the selected HRQoL model in predicting mortality during the next 5 years.
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4.3.2  HRQoL development in Asthma and COPD – focus on signi? cant 
individual trajectories
Th e individual trajectories of HRQoL over the 5-year follow-up time were assessed in 
the Project II when patients had a variable number of HRQoL measurements distributed 
unevenly in time. A linear mixed eff ects model (Robinson 1991) was used to model the 
trajectories consisting of multiple measurements. Th e Best Linear Unbiased Predictors 
(BLUPs) for trajectory and intercept were let to vary at random from patient to another as 
it is assumed that patients present variation in their baseline and trajectories of HRQoL. 
Subsequently Markov Chain Monte Carlo simulations using Bayesian inference (Martin, 
Quinn et al. 2011) were run to create a sample of the posterior distribution of the trajectories 
to identify individual patients with signifi cant decline. Th e decline was considered signifi cant 
when 85% of the simulated samples were negative (85% probability level) for a particular 
patient. ROC and AUC statistic were used to estimate the value of cross-sectional HRQoL 
measurement in predicting future development. Optimal cut points were determined for 
cross-sectional HRQoL-measurement to estimate the Odds Ratios related to lower baseline 
HRQoL in future HRQoL development. Bayesian Models Averaging (Wintle, McCarthy et al. 
2003) was used to determine the important determinants of the development of HRQoL by 
means of averaging over the competing models to estimate the posterior eff ect probabilities 
for each variable in the input (Hoeting 1999). Clinical determinants possibly aff ecting the 
development were included in a generalized linear model when trajectories of HRQoL were 
treated as a continuous outcome. Missing values in the 15D questionnaire were imputed up 
to three dimensions using a regression method based on other dimensions with an algorithm 
provided with 15D instruments (Sintonen 1994). 
4.3.3  Lung func? on development in COPD – assessing the variability and 
iden? fying individual trends in unbalanced data set
Th e focus of the Project III was on individual FEV1 trajectories over time, again distributed 
unevenly between patients and over time. Th e number of available measurements varied 
greatly between patients. Th us a Hierarchical Bayesian Model (Gelman, Hill 2007) was 
used to allow the fl exible estimation of the model parameters using a non-informative prior 
distribution. Linear fi t was assumed as the aim of this study was not to assess the age or time 
eff ects in trajectories. Linear fi t is also less prone to overfi tting. Logistic regression was used 
to determine the clinical determinants associated with signifi cant lung function decline. 
4.3.4  Gene? c background of lung func? on development 
Lung function development in project IV was calculated by subtracting the FEV1 of the 
year 2000 from the FEV1 of the year 2011. Estimating the heritability of the lung function 
parameters was based only on genotyped (HumanHap610-Quad Genotyping BeadChip) 
common variants (SNP Minor Allele Frequency, MAF >5%).  Quality Control (QC) 
(Turner, Armstrong et al. 2011) was performed to exclude individuals and markers with call 
Material and Methods
26
rate <95%. Individuals were also excluded due to unexpected relatedness, unusually high 
heterozygocity and gender checks while SNPs were excluded due to deviations from the 
Hardy-Weinberg equilibrium <1×10-6. A suggested method (Yang, Benyamin et al. 2010) 
aims to estimate the narrow sense heritability of unrelated subjects by fi tting the SNP eff ects 
(Identity by State matrix) in a mixed eff ects model. SNP eff ects were included as random 
eff ects to estimate the variance explained while assessing the eff ects simultaneously. 
Prior to the screening of the genetic association, SNPs with call rate <99% were further 
excluded to allow robust genotype imputation using the 1000 Genomes reference panel 
with added subjects from the Finnish population (Sequencing Initiative Suomi). Genotype 
imputation was done to achieve a more comprehensive set of SNPs while it was based on 
predicting the variants by using the genotyped variants and a dense reference panel of 
haplotypes. Th e two haplotypes were then compared and aligned and missing genotypes 
imputed according to the reference panel (Marchini, Howie 2010). 
Screening for variants associated with the FEV1 development during the follow-up was done 
on residuals adjusted for possible confounding variables and population structure by using 
multidimensional scaling (Purcell, Neale et al. 2007) to avoid spurious associations. Th e 
residuals were transformed to ranks and subsequently to Z-scores for screening in SNPTEST 





5.1  Poor HRQoL in COPD is associated with characteris? c 
determinants depending on severity of disease
Compared to age and gender matched Finnish population the COPD patients in FinnCad-
cohort were found to oft en suff er from major comorbidities previously known to be 
associated with COPD. Th e prevalence of the comorbidities was, however, lower compared 
to some previous reports in COPD cohorts.
Comorbidities were found to contribute to the generic HRQoL signifi cantly as standardized 
regression estimates were found comparable for psychiatric conditions and FEV1 while 
alcohol abuse, cardiovascular diseases, diabetes and arterial hypertension contributed as 
well. Respiratory specifi c AQ20 was found mostly aff ected by FEV1 followed by psychiatric 
conditions, female gender, alcohol abuse and hypertension. 
Risk factors for very low HRQoL in 15D were psychiatric conditions (Odds Ratio, OR = 4.7, 
p <0.001), FEV1 <40% of predicted (OR = 3.1, p = 0.03), alcohol abuse (OR = 2.3, p = 0.007) 
and diabetes (OR = 2.1, p = 0.03). 
AQ20 was mostly aff ected by lung function as FEV1 <40 % of predicted was associated with 
OR=5.2 (p=0.001), but also FEV1 40-64% (OR=2.5, p=0.05) had an eff ect. Alcohol abuse 
(OR=3.0, p=0.001), female gender (OR=2.1, p=0.004) and psychiatric conditions (OR=2.0, 
p=0.007) were also associated with poor airway specifi c HRQoL.
Th e risk factors identifi ed for poor HRQoL were also associated with 5-year mortality while 
FEV1 <40% was found to have a considerable eff ect (OR=6.9, p0.001). Alcohol abuse and 
cardiovascular diseases were found to contribute a well. For both instruments the overall 
HRQoL score was clinically and signifi cantly lower at baseline in patients who died during 
the 5-year period. 
5.2  Individual HRQoL trajectories are iden? ? able in Asthma and 
COPD
During the 5-year follow-up period most of the COPD patients (60–80% depending on the 
questionnaire used) showed decline in their HRQoL, whereas in asthma the majority (46–
71%) presented no decline. Both asthma and COPD showed decline more oft en with the 
generic 15D. 
With the use of the 15D, 6% of both asthma and COPD patients were shown to present 
signifi cant decline. Quantifi ed by Minimum Clinically Important Diff erence (MCID), the 
signifi cant decliners reached MCID in two years in both asthma and COPD. In the residual 
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patients the mean time to MCID in asthma would take 75 years and 7 years in COPD. 
Th e number of valid measurements over time was suggested to be important as most of 
the signifi cant decliners were identifi ed with 4 (against 3) measurements over the 5-year 
follow-up (77–96% depending on diagnosis and instrument).
Signifi cant decline could be predicted with the low baseline HRQoL alone while the optimal 
cut-points were associated with signifi cant decline: OR = 4–6 depending on the instrument 
in asthma and OR = 5–11 in COPD respectively.
Clinical determinants for signifi cant decline in asthma were obesity linked, such as 
hypertension, diabetes mellitus and gastroesophageal refl ux disease. Decline in COPD was 
associated with increasing age and lung function level. Psychiatric conditions were associated 
with decline in both asthma and COPD.
5.3  Longitudinal FEV1 presents varia? on in COPD, but individual trajectories are iden? ? able
Development of pre-bronchodilatory FEV1 in COPD presented variation at the cohort 
level while positive trajectories were detected for 10% of the cohort population. Th us a 
great majority, 90% of the cohort population, presented decline of FEV1 during the variable 
follow-up period (mean 5 years) with highly variable number of measurements for each 
patient (mean 8 measurements).
However, when the individual trajectories were assessed, we found that there was signifi cant 
improvement in 2% and decline in 30% of the population. 68% of the population did not 
present any signifi cant development at 95% probability level suggesting signifi cant diversity 
in the development of FEV1 in COPD. Signifi cant decliners could not be identifi ed accurately 
from the distribution of trajectories as there was considerable overlap in the development in 
decliners and non-decliners (Figure 1.).
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Figure 1. Development of FEV1 in the cohort. Signifi cant decliners (grey) and non-decliners (black) 
present considerable overlap in the development of FEV1.
Th e uncertainty related to each trajectory is not observed unless the patients are assessed 
individually (Figure 2.). Two patients might have identical trajectories (a line fi tted on 
measurements of FEV1 in time), but the other might not present statistically signifi cant 
decline and is thus not labelled as a signifi cant decliner.
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Figure 2. Random sample of trajectories of FEV1 (litres) over time. Signifi cant decliners are indicated in 
grey.
Signifi cant decline was found associated with several disease exacerbation related 
markers such as emergency visits, hospital admissions, pneumonias and purchases of oral 
corticosteroids or antibiotics. Common comorbidities were not found associated with the 
decline while continuous smoking was found to be borderline signifi cant.
5.4  Heritability and gene? cs of lung func? on trajectories
In the Project IV it was suggested that the variation in FEV1 development in a randomly 
chosen population cohort is notably aff ected by genetic markers. Th e variation explained 
was estimated at 31% (Likelihood Ratio Test p-value = 0.07) for the level of FEV1 at the start 
of the follow-up and 32% (p = 0.02) for the development of FEV1.
Of the previously known loci for FEV1 level or development or COPD status, only one locus 
was seen associated. Most signifi cant SNP in the C10orf11 locus was rs7476758 (p=8.2×10-4). 
C10orf11 was not found to be notably expressed in human lung (GTEx Consortium 2015).
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Th e GWA screening was performed to identify the loci associated with FEV1 development 
as two suggestive associations were found. In 1p31.1 the most signifi cant SNP was an 
intronic rs10874272 (p-value=4.11×10-7), which was in Linkage Disequilibrium in regard 
to neighbouring SNPs, and Minor Allele Frequency was found to be 19%. Th e SNPs are 
located on the LPHN2 gene, which was found to be the most notably expressed in human 
lung of all tissues with Reads Per Kilobase per Million mapped reads (RPKM) of 29.4 (GTEx 
Consortium 2015). 
Th e other novel association for rs9599484 (p=3.99×10-7) was found in 13q13.3 with a MAF 
of 6% and in strong Linkage Disequilibrium (LD) to neighbouring SNPs. Th e nearest genes 
in the region were LINC00457 and NBEA, which were not found notably expressed in 





In this thesis we have identifi ed comorbidities with major eff ect on the Health Related 
Quality of Life in mild or moderate COPD as the comorbidities were found to play a 
minor role also in severe COPD. We identifi ed signifi cantly poor development of HRQoL 
in individual patients both in asthma and COPD during the 5-year follow-up when the 
major determinants of poor development were characteristic of asthma and COPD. We 
found that while the variation in the development of lung function in COPD is abundant, 
individual trajectories are identifi able. Signifi cant decline in lung function was associated 
with numerous exacerbation related markers. In the unpublished Project IV results suggest 
that the decline of lung function in the Finnish population is signifi cantly aff ected by genetic 
variation. A previously reported locus (c10orf11) for FEV1 level was also found associated 
with the development of lung function. GWA screening suggests two novel loci (LPHN2 and 
LINC00457/NBEA) associated to lung function development. 
6.1  HRQoL in mild or moderate COPD is greatly a? ected by 
comorbidi? es
Although the prevalence of comorbidities has been studied in COPD, their relative eff ect on 
HRQoL has not been assessed. In addition, HRQoL in COPD has not been widely studied 
and the role of comorbidities, when recognized, has remained under speculation (Curtis, 
Deyo et al. 1994, van Manen, Bindels et al. 2001, Burgel, Escamilla et al. 2013, Putcha, Puhan 
et al. 2013). Our results suggest that the common comorbidities play an integral part in mild 
or moderate COPD whereas in severe COPD the HRQoL is mostly aff ected by poor lung 
function. Th e number of comorbidities was not found signifi cant, a congruent fi nding with 
previous fi ndings (Putcha, Puhan et al. 2013). Th e model built to describe poor HRQoL also 
showed predictive ability of mortality during the 5-year follow-up.
HRQoL is oft en a secondary endpoint in studies with multiple exclusion criteria (Calverley, 
Anderson et al. 2007, Decramer, Celli et al. 2009), and thus a considerable number of 
patients are excluded from the analysis for justifi ed reasons. Th is aff ects the prevalence of 
comorbidities in trials as some are deliberately excluded to improve the internal validity of a 
trial. Also, as a diagnosis found in medical records was required in contrast to self-reported 
comorbidity, the prevalence of comorbidities was lower compared to some previous studies. 
However, the external validity suff ers from the extent of exclusion criteria as in random 
population of COPD patients only 5% were found to fulfi ll the inclusion criteria for the 




6.2  HRQoL in asthma and COPD during the 5-year follow-up
To our knowledge, individual trajectories of HRQoL have not been previously assessed 
in clinical pulmonology and the fi rst fi ndings of patient-level trajectories are presented in 
the Project II. Our results suggest that asthmatic patients oft en avoid the decline of HRQol 
especially when generic HRQoL is assessed. COPD patients, however, oft en presented 
progressive loss of HRQoL and also reached the Minimum Clinically Important Diff erence 
in a shorter period of time compared to asthmatics. Signifi cant individual decline was seen 
for both asthma and COPD using both generic and airway specifi c instruments. Clinical 
determinants of decline in asthma were obesity related diseases and states while decline 
in COPD was aff ected by lung function and increasing age. Psychiatric conditions were 
suggested to be an important determinant for both asthma and COPD.
6.3  Individuals with rapid decline of lung func? ons
Th e development of lung function has only recently been assessed more thoroughly 
(Nishimura, Makita et al. 2012, Vestbo, Edwards et al. 2011, Casanova, de Torres et al. 2011, 
Tantucci, Modina 2012, Tashkin 2013, Tashkin, Li et al. 2013) and individual (patient-
level) trajectories are still poorly known (Casanova, de Torres et al. 2011, Tashkin 2013). 
Th e use of retrospective and un-balanced data was shown to produce results comparable 
to previous prospective studies when the cohort-level development was assessed. We were 
able to identify a notable fraction of patients (30% of cohort) as signifi cant decliners when 
compared to the only previous report (Casanova, de Torres et al. 2011). Previous studies 
have found the prevalence of improving trajectories unexpectedly common considering 
the progressive nature of COPD up to 15% of cohort population (Vestbo, Edwards et al. 
2011). Our results underline the importance of assessing the individual trajectories and the 
uncertainty related to them as signifi cantly improving trends were found in only 2% of the 
cohort population. 
Signifi cant decline was associated with exacerbation related markers further strengthening 
the conception of overlap of the frequent exacerbator and rapid decliner phenotype (Anzueto 
2010).
As the cohort represented hospital based COPD patients, even the patients with the most 
severe disease were not lost from follow-up, which is common in prospective studies and 
might have a notable eff ect on inferences of randomized controlled trials (Akl, Briel et al. 
2012). 
As spirometry is a non-invasive and oft en used examination in clinical medicine, analysis of 
lung function trajectories might be used as an endpoint in genetic analysis.
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6.4  Heritability and gene? c suscep? bility of lung func? on 
development
So far, only estimates from familial or twin studies exist to assess the amount of genetic 
markers explaining the phenotypic variation of lung function development (Hukkinen, 
Kaprio et al. 2011, Gottlieb, Wilk et al. 2001). Th is study suggests the fi rst SNP-based 
estimate for heritability of FEV1 development, which was found substantial and signifi cantly 
diff erent from zero. Th is estimate is also the fi rst to assess the FEV1 level heritability in the 
general population as previous SNP-based estimate is based on cohort of heavy smokers. 
As the level of lung function, or as in this study, especially the development of lung function 
is of interest, it should be noted that estimates also include remnants of determinants 
essential in developing lung function in utero and during childhood. More studies are 
needed to clarify age-specifi c eff ects also in adulthood.
Of the previously known loci associated with the FEV1 level, development of FEV1 or 
COPD disease status, only one locus was found associated with the development of FEV1 
in the present study. Th is suggests that diff erent loci are causal to lung function level and 
development. Our results suggest novel association in two loci: LPHN2 (p-value 4.11×10-7) 
and LINC00457/NBEA (p=3.99×10-7). LPHN2 is mostly expressed in human lung (GTEx 
Consortium 2015) and has been previously found mutated in non-small cell lung carcinomas 





Asthma and COPD are major causes of morbidity, and according to the World Health 
Organization COPD will become the third leading cause of death worldwide by 2030 
(World Health Organization). In Finland, the prevalence of COPD in males aged 65–74 
years has been found to be 13% (Vasankari, Impivaara et al. 2010) as even 50% of smokers 
are estimated to develop COPD (Lundback, Lindberg et al. 2003). COPD is considered a 
progressive disease leading to disabilities unless smoking is discontinued and thorough 
medical and lifestyle changes are introduced (Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) 2015). So far though, the progression of lung function obstruction has not 
been assessed extensively, and the amount of heritable markers aff ecting the development is 
poorly known. Th is study provides perspectives on the development of HRQoL and FEV1 
to better understand the entities of lung function development and signifi cant individual 
trajectories.
Th e results of this study suggest that Health Related Quality of Life (HRQoL) is notably 
aff ected by common comorbidities in COPD. Obesity-related comorbidities and 
characteristics were found signifi cantly associated with the development of HRQoL in 
asthma, whereas in COPD, the main determinants were increasing age and the severity 
of lung function obstruction. Severe psychiatric conditions were seen as determinants of 
development of HRQoL both in asthma and COPD. 
Th e development of lung function was seen variable between individuals and signifi cant 
individual trajectories were identifi ed. Th e development of lung function was shown to be 
substantially aff ected by genetic markers and should continue to be analysed in the future.
Th is study is mostly based on Electronic Health Records (EHRs) and thus is more prone to 
bias compared to prospective studies as the use of retrospective data needs to be shown valid 
for decision-making in medical research. However, the use of EHRs could prove fruitful as 
it off ers considerably lower costs and does not require a period of time aft er study initiation 
before the analysis can be performed as the data is already available. In future, clinical data 
will be increasingly released from hospitals to researchers, but the potential can only be 
utilized if the data can be treated correctly. 
Nowadays, medicine is designed for the “average patient”, and not enough attention is paid 
to individuals presenting deviation from the average. Th e trajectories in clinical medicine are 
determined at the group level to account for random error related to individual trajectories. 
As moving towards P4 medicine (preventive, predictive, personalized and participatory 
medicine), assessing individual trajectories has become more momentous (Hood 2013). 
However, it is challenging as biological processes/physiological measurements include 
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random variation due to measurement errors and natural (e.g. daily) oscillation in the state. 
Th e within-subject variation needs to be assessed as trajectories present between-subject 
variation, which could be taken advantage of in future studies. Signifi cant trajectories 
could be accentuated in the analysis while insignifi cant trajectories would be given less 
weight. Th us, the analysis would not be based on the distribution of trajectories but on the 
combination of trajectories and their credibility. 
In clinical medicine, the level of a parameter or measurement has the highest value at the 
time of diagnosis, aft er which the future values are compared to the fi rst ones. Th is underlines 
the importance of the trajectories as development within a parameter is always relevant and 
calls for their assessment in the future. As the level of FEV1 always contains some of the 
decline aft er reaching its full volume in early adulthood, it would be necessary to assess 
whether the same determinants have an eff ect on the decline of FEV1 throughout the human 
lifespan. Diagnosis of COPD is made cross-sectionally, which has been shown to lead to 
overestimation of COPD in the elderly and underdiagnosis in the young (Hardie, Buist et al. 
2002, Swanney, Ruppel et al. 2008, Cerveri, Corsico et al. 2008). Th e diagnosis could be more 
accurate when based on the development of lung function in uncertain cases. Th is study 
suggests that rapid decliners are identifi able from real-world clinical data, which enables 
the targeting of medical interventions eff ectively to those in risk of disability and mortality. 
Th e decline of FEV1, especially if more thoroughly investigated for age and period eff ects, 
could prove useful as an endpoint in genetic analysis. As typical eff ect sizes (Odds Ratio) in 
case-control GWA studies are in the range of 1.1–1.3, the accuracy of diagnosis is of critical 
importance as 70% sensitivity and specifi city can defl ate ORs of 1.3 due to non-diff erential 
misclassifi cation (Szklo, Nieto 2014b). Th erefore, the phenotypes used in genetic analysis 
should be relevant and well-defi ned. Th e phenotypes in question could represent clinically 
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